Preladenant
Preladenant
Preladenant (pronunciation: pre-lad-en-ant) is a selective antagonist of the adenosine A2A receptor. It was developed by Schering-Plough and later by Merck & Co. for the treatment of Parkinson's disease and other related neurological disorders.
Etymology
The term "Preladenant" is derived from the words "pre" meaning before, and "adenant" which is a shortened form of "adenosine antagonist". The name signifies its function as a pre-emptive blocker of the adenosine A2A receptor.
Function
Preladenant works by selectively blocking the adenosine A2A receptor. This receptor is found in the brain and is involved in the regulation of glutamate and dopamine, two neurotransmitters that are crucial for motor function. By blocking this receptor, Preladenant can help to alleviate the symptoms of Parkinson's disease.
Related Terms
- Adenosine A2A receptor: A protein that is encoded by the ADORA2A gene in humans. Preladenant is a selective antagonist of this receptor.
- Schering-Plough: A United States-based pharmaceutical company that developed Preladenant.
- Merck & Co.: A multinational pharmaceutical company that continued the development of Preladenant after acquiring Schering-Plough.
- Parkinson's disease: A long-term degenerative disorder of the nervous system that mainly affects the motor system. Preladenant was developed for the treatment of this disease.
External links
- Medical encyclopedia article on Preladenant
- Wikipedia's article - Preladenant
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski